

Case studies on drug development and novel targets from Glenmark Pharmaceuticals and Novartis at COPD 2016

SMi Reports: Glenmark Pharmaceuticals and Novartis Pharma to join the speaker line up at this years' COPD conference in London on 19-20th October.

LONDON, UNITED KINGDOM, July 14, 2016 /EINPresswire.com/ -- [COPD](#) 2016 will gather a global audience of respiratory professionals and lead scientists for a packed 2 day agenda. The event will take place on 19-20th October in London. Day 1 will address topics such as pre-clinical and clinical development, COPD exacerbations, advances in patient monitoring, while Day 2 explores drug development and novel targets and will include interactive panel discussion: developing clinical trials for COPD.

The conference will feature expert speakers from Glenmark Pharmaceuticals, Novartis Pharma, the National University of Singapore, and many more.

Neelima Khairatkar Joshi, Sr. Vice President of Glenmark Pharmaceuticals will be speaking about COPD lung: inflammation and remodelling, novel targets and learning so far. During her presentation on day two, Neelima will also discuss lung pathology: blind men - elephant story?

Dr. Frank Thielmann, Lead Inhalation New Solids, Novartis Pharma will be presenting his case study on advances in device and formulation technologies for pulmonary drug delivery. Dr. Thielmann will focus on state of the art formulation technologies for pulmonary drug delivery, device y-formulation interaction and trends in device development.

Furthermore, Dr. Fred Wong, Head & Associate Professor of the Department of Pharmacology at the National University of Singapore will be presenting an overview from APAC and sharing his experience on free radical-neutralizing capability of γ -tocotrienol and anti-inflammatory properties of γ -tocotrienol. The presentation will also highlight oxidative stress and damage in COPD.

For more information about the event please visit: www.copd-conference.co.uk/ein



Other expert speakers include:

- Stephen Beckman, Head of Global Respiratory and Allergy, Mylan, Inc.
- Dr Mario Scuri, Head Respiratory Unit, Chiesi Pharmaceuticals
- Dr Christopher Stevenson, Venture Leader, COPD Interception, Janssen Pharmaceutical Companies of Johnson & Johnson
- Dr Jonathan Phillips, Principal Scientist, Amgen
- Dr Beverley Patterson, Inhalation Clinical Associate Director, Actavis, and many more.

For delegate enquiries contact Matthew Apps +44 (0) 20 7827 6093 or email mapps@smi-online.co.uk

For sponsorship opportunities contact Alia Malick on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk

For media enquiries please contact Anna Serazetdinova on +44 20 7827 6180 or aserazetdinova@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

More information can be found at <http://www.smi-online.co.uk>

Anna Serazetdinova
SMi Group Ltd
+44702078276180
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.